Literature DB >> 3343691

Multiple markers for lung cancer diagnosis: validation of models for localized lung cancer.

M H Gail1, L Muenz, K R McIntire, B Radovich, G Braunstein, P R Brown, L Deftos, A Dnistrian, M Dunsmore, R Elashoff.   

Abstract

Sera from 71 patients with localized lung cancer, from 70 normal controls, and from 73 patients with benign lung diseases were analyzed for 10 substances to detect lung cancer: ferritin, lipid-bound sialic acid, total sialic acid, beta 2-microglobulin, lipotropin, the alpha and beta subunits of human chorionic gonadotropin, calcitonin (two assays), parathyroid hormone, and carcinoembryonic antigen (CEA). Individual markers were studied, and optimal combinations of markers were sought for discriminating patients with localized lung cancer from normal controls and from patients with benign lung disease. Both logistic regression and recursive partitioning methods for discrimination were tried. The best rules involved only CEA and ferritin for discriminating patients with lung cancer from normal controls, and CEA and age for discriminating patients with lung cancer from those with benign lung diseases. The performance of these rules was validated on an independent serum panel containing sera from 56 patients with localized lung cancer, 75 normal controls, and 75 patients with benign lung diseases. Three rules designed to achieve 95% specificity against normal controls attained 14%-36% sensitivity for localized lung cancer in the validation panels, whereas three rules designed to achieve 95% specificity against benign lung diseases attained 30%-39% sensitivity. Some aspects of potential clinical applications are discussed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3343691     DOI: 10.1093/jnci/80.2.97

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  7 in total

1.  NDRG1/Cap43 overexpression in tumor tissues and serum from lung cancer patients.

Authors:  D Wang; X Tian; Y Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2012-06-22       Impact factor: 4.553

2.  Paraneoplastic syndromes in 68 cases of resectable non-small cell lung carcinoma: can they help in early detection?

Authors:  N Campanella; A Moraca; M Pergolini; W Daher; A Fianchini; A Sabbatini; A Brunelli; M Al-Refai
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

3.  DIFFERENTIAL SERUM LEVEL OF SPECIFIC HAPTOGLOBIN ISOFORMS IN SMALL CELL LUNG CANCER.

Authors:  Ankur Shah; Harpreet Singh; Vibhu Sachdev; James Lee; Sohiya Yotsukura; Ravi Salgia; Ajit Bharti
Journal:  Curr Proteomics       Date:  2010-04-01       Impact factor: 0.837

4.  A comprehensive peptidome profiling technology for the identification of early detection biomarkers for lung adenocarcinoma.

Authors:  Koji Ueda; Naomi Saichi; Sachiko Takami; Daechun Kang; Atsuhiko Toyama; Yataro Daigo; Nobuhisa Ishikawa; Nobuoki Kohno; Kenji Tamura; Taro Shuin; Masato Nakayama; Taka-Aki Sato; Yusuke Nakamura; Hidewaki Nakagawa
Journal:  PLoS One       Date:  2011-04-12       Impact factor: 3.240

5.  Thioredoxin Reductase as a Novel and Efficient Plasma Biomarker for the Detection of Non-Small Cell Lung Cancer: a Large-scale, Multicenter study.

Authors:  Suofu Ye; Xiaofeng Chen; Yi Yao; Yueqin Li; Ruoxuan Sun; Huihui Zeng; Yongqian Shu; Hanwei Yin
Journal:  Sci Rep       Date:  2019-02-25       Impact factor: 4.379

6.  The Marker State Space (MSS) method for classifying clinical samples.

Authors:  Brian P Fallon; Bryan Curnutte; Kevin A Maupin; Katie Partyka; Sunguk Choi; Randall E Brand; Christopher J Langmead; Waibhav Tembe; Brian B Haab
Journal:  PLoS One       Date:  2013-06-04       Impact factor: 3.240

7.  Nonspecific crossreacting antigen (NCA) is a major member of the carcinoembryonic antigen (CEA)-related gene family expressed in lung cancer.

Authors:  T Hasegawa; K Isobe; Y Tsuchiya; S Oikawa; H Nakazato; I Nakashima; K Shimokata
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.